Posted by Michael Wonder on 28 Jun 2023
Cyltezo, first interchangeable biosimilar to Humira, receives preferred formulary status with Optum Rx for commercially insured patients
23 June 2023 - Cyltezo will be commercially available in the US on 1 July 2023.
Boehringer Ingelheim today announced that Optum Rx, a pharmacy benefit manager and subsidiary of UnitedHealth Group, will place Cyltezo (adalimumab-adbm) on its commercial formulary as a preferred brand, which covers more than 66 million members.
